Position in IBIO
as of Mar 31, 2026
· filed May 4, 2026
Position Value
$129,344
-$747,050 QoQ
Shares Held
68,076
-93.6% QoQ
Ownership
0.106%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
8 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in IBIO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Lynx1 Capital Management LP holds $865,408,538 across 26 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GHRS |
GH Research PLC
|
13,263,288 | $356,517,181 | |
| 2 | CGEM |
Cullinan Therapeutics, Inc.
|
8,963,500 | $163,225,335 | |
| 3 | STOK |
Stoke Therapeutics, Inc.
|
4,038,404 | $132,136,578 | |
| 4 | AGIO |
Agios Pharmaceuticals, Inc.
|
3,408,937 | $126,505,652 | |
| 5 | CCCC |
C4 Therapeutics, Inc.
|
7,326,691 | $34,215,646 | |
| 6 | KRRO |
Korro Bio, Inc.
|
1,538,296 | $20,274,741 | |
| 7 | TCRX |
TScan Therapeutics, Inc.
|
8,019,148 | $7,858,765 | |
| 8 | DTIL |
Precision Biosciences Inc
|
950,466 | $7,470,662 |
All Filings in IBIO
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $129,344 | 68,076 | Shares | Other | 2026-05-04 | |
| 2025-09-30 | $876,394 | 1,055,897 | Shares | Other | 2025-11-13 | |
| 2025-06-30 | $1,169,315 | 1,538,573 | Shares | Other | 2025-08-14 | |
| 2025-03-31 | $3,466,361 | 862,279 | Shares | Other | 2025-05-15 | |
| 2024-12-31 | $2,112,583 | 862,279 | Shares | Other | 2025-02-14 | |
| 2024-09-30 | $1,914,259 | 862,279 | Shares | Other | 2024-11-14 | |
| 2024-06-30 | $508,009 | 240,763 | Shares | Other | 2024-08-14 | |
| 2024-03-31 | $2,436,000 | 600,000 | Shares | Other | 2024-05-30 | |
| No filing history on record for this holder in this stock. | ||||||